SAN

73.175

+0.18%↑

SRT3

216.15

+0.51%↑

ORNBV.FI

67.2

-1.97%↓

PHMA

95.6

-1.49%↓

DRW3

87.45

-2.67%↓

SAN

73.175

+0.18%↑

SRT3

216.15

+0.51%↑

ORNBV.FI

67.2

-1.97%↓

PHMA

95.6

-1.49%↓

DRW3

87.45

-2.67%↓

SAN

73.175

+0.18%↑

SRT3

216.15

+0.51%↑

ORNBV.FI

67.2

-1.97%↓

PHMA

95.6

-1.49%↓

DRW3

87.45

-2.67%↓

SAN

73.175

+0.18%↑

SRT3

216.15

+0.51%↑

ORNBV.FI

67.2

-1.97%↓

PHMA

95.6

-1.49%↓

DRW3

87.45

-2.67%↓

SAN

73.175

+0.18%↑

SRT3

216.15

+0.51%↑

ORNBV.FI

67.2

-1.97%↓

PHMA

95.6

-1.49%↓

DRW3

87.45

-2.67%↓

Accueil・Liste d'Actions・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

79.55 1.66

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

79.55

Max

79.8

Chiffres clés
By Trading Economics
Revenu	-33M 43M
Ventes	7.9M 218M
P/E Moyenne du Secteur	33.502 49.8
BPA	0.834
Marge bénéficiaire	19.539
Employés	1,950
EBITDA	-21M 63M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+32.46% upside

Dividendes
By Dow Jones
Prochains Résultats	23 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	84M 4.1B
Ouverture précédente	77.89
Clôture précédente	79.55

Sentiment de l'Actualité

By Acuity

50%

175 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

51.1 / N/A Support & Résistance

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 mai 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mai 2026, 22:32 UTC

Résultats

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mai 2026, 22:02 UTC

Market Talk

Principaux Événements d'Actualité

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mai 2026, 21:49 UTC

Résultats

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mai 2026, 21:23 UTC

Acquisitions, Fusions, Rachats

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mai 2026, 21:12 UTC

Résultats

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mai 2026, 21:12 UTC

Résultats

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 mai 2026, 20:44 UTC

Résultats

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mai 2026, 20:43 UTC

Résultats

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Rev $136.4M >CLSK

11 mai 2026, 20:30 UTC

Résultats

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Cont Ops EPS $2.24 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Rev $1.6B >STE

11 mai 2026, 20:30 UTC

Résultats

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Adj EPS $2.83 >STE

11 mai 2026, 20:22 UTC

Actions en Tendance

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mai 2026, 19:37 UTC

Résultats

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

32.46% hausse

Prévisions sur 12 Mois

Moyen 83.25 EUR 32.46%

Haut 83.5 EUR

Bas 83 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

175 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.